SLE is a chronic systemic autoimmune disease characterized by a breakdown of tolerance to nuclear antigens and generation of high-affinity pathogenic autoantibodies. These autoantibodies form, with autoantigens, immune complexes that are involved in organ and tissue damages. Understanding how the production of these pathogenic autoantibodies arises is of prime importance. T follicular helper cells (Tfh) and IL-21 have emerged as central players in this process. This article reviews the pathogenic role of Tfh cells and IL-21 in SLE. 
Introduction
SLE is a chronic, prototypical, systemic autoimmune disease characterized by a breakdown of tolerance to nuclear antigens [1] . The pathogenesis of SLE is a complex process involving genetic, environmental, hormonal and immunological factors [1] . A better understanding of human SLE pathogenesis is needed in order to develop effective and safe targeted therapies.
The production of autoantibodies against nuclear components, i.e. ANAs, is characteristic of the disease and appears to be fundamental for pathogenesis [1] . Therefore, understanding how the production of these autoantibodies arises is crucial. T follicular helper (Tfh) cells, a recently described novel subset of Th cells, play a critical role in the development of T celldependent B cell responses and seem to be compulsory for pathogenic autoantibody production [2] . In this review we will discuss the role of Tfh cells and IL-21, a major cytokine produced by Tfh cells, in SLE.
Tfh cells

Tfh cells represent a CD4
+ helper T cell subset specialized for provision of help to B cells, which was initially described in humans in 2000 and 2001 [36] . These cells can be identified by a combination of markers, including high expression of chemokine (C-X-C motif) receptor 5 (CXCR5) [3, 6] , co-stimulatory molecules [inducible co-stimulator (ICOS)] [3] and programmed cell death 1 (PD-1), as well as expression of the transcription repressor B cell lymphoma 6 (Bcl-6). These molecules serve as markers of Tfh lineage, but also have important roles for their generation and functions. CXCR5 is a B cell zone homing chemokine receptor, required for T cell migration into follicles and for their colocalization with B cells, in response to the specific ligand CXCL13 [79] . CXCR5 is necessary for the germinal centre (GC) formation [10, 11] . Bcl-6 is necessary for full Tfh cell maturation [1214] . Bcl-6 represses other Th cell programmes by inhibiting the expression of transcription factors T-bet, GATA-3 or RORgt, important for Th1, Th2 and Th17 cells, respectively [12, 13, 15] . Bcl-6 acts antagonistically with another transcription repressor called B lymphocyteinduced maturation protein 1, which negatively regulates Tfh development [14] .
Differentiation 
Role of Tfh cells in SLE pathogenesis
In SLE, B cell abnormalities indicate that autoantibodyproducing B cells are derived from GCs [54] . Thus data from murine models or from human SLE demonstrated Tfh cells as important actors for lupus pathogenesis.
Tfh cells in murine models
A number of studies with lupus-prone mouse models demonstrated that Tfh cells contribute to lupus pathogenesis. An autoimmune mouse strain, sanroque mice, has a particular mutation in roquin, a gene encoding for a RINGtype ubiquitin ligase family member that post-transcriptionally regulates gene expression [55] . The phenotype of sanroque mice is characterized by high levels of ANAs, autoimmune thrombocytopenia, GN with immune complex deposits and peripheral lymphadenopathy with splenomegaly [55] . The sanroque mice and the mice deficient for the two Roquin paralogs (Roquin-1 and Roquin-2) display increased Tfh cells [5557] with high expression of ICOS [55] and present excessive GC formation, even in the absence of antigen stimulation [5558] . Roquin-1 and Roquin-2 post-transcriptionally regulate the expression of ICOS and OX40 [56, 57] . In this model, heterozygous Bcl6 deficiency results in a reduction in the number of GC cells and leads to attenuation of the pathology, suggesting that autoimmunity is dependent on GC formation and excessive Tfh cell activity [58] .
The BXSB-Yaa mouse model, which carries the Y-linked autoimmune accelerator mutation Yaa (duplication of the Tlr7 gene), develops severe inflammatory disease, with expanded numbers of B cells, hypergammaglobulinaemia, high levels of autoantibodies, proliferative GN and decreased longevity [59] . These animals present high proportions of Tfh cells in their spleens [60] .
In addition, reports on the NZB/NZW mouse model provide arguments that interactions between ICOS and its ligand are critical for development of the disease [61, 69, 71] . Following treatment of SLE with steroids and/or immunosuppressive drugs, the number of activated cTfh cells decreased [66, 71] , concomitant with clinical amelioration [71] .
Some reports suggest an association between expansion of activated cTfh cells and disease activity assessed by the SLEDAI [52, 71, 72] , supporting the interest of Tfh cells as a potential biomarker in SLE. But others fail to highlight such an association [69, 70] . For example, Choi et al. [69] recently concluded that there was no correlation between the percentage of CXCR5 high ICOS high PD-1 high circulating cells and SLEDAI. Only the intensity of the expression of PD-1 by Tfh cells was associated with the severity of disease activity and with the presence of past serositis, proteinuria, haematuria, pyuria, high levels of anti-dsDNA antibodies and hypocomplementemia [69] .
Regarding cTfh cell subsets, recent studies have shown that SLE patients have alterations in the composition of subsets, which were also associated with disease activity [73] . The ratio of cTfh2 and cTfh17, which are efficient B helpers [50], over cTfh1 was significantly increased in SLE patients compared with controls. Furthermore, cTfh2 cell frequency was correlated with the SLEDAI, whereas cTfh1 cell frequency was inversely associated, and both subsets were related to the presence of anti-dsDNA antibodies [73] .
At the tissue level, Tfh-like cells have been identified in kidney of patients with lupus nephritis [74, 75] . They aggregate with B cells within the tubulointerstitium and sometimes organize structures similar to GCs in secondary lymphoid organs [75] . These infiltrating cells might be associated with B cell clonal selection and expansion at inflammatory sites [75] .
As in murine models, reports investigated the role of the ICOS pathway in SLE pathogenesis [7678] . ICOS expression is enhanced on CD4 + and CD8 + T cells in peripheral blood of SLE patients compared with controls [77] and the proportion of peripheral blood T cells expressing ICOS is higher in patients with active disease than in patients with inactive disease or in controls [76] . ICOS co-stimulation of T cells enhances in vitro the production of anti-dsDNA antibodies by autologous B cells from SLE patients [76, 78] . Direct mechanisms involved in enhanced Tfh response in SLE patients have been recently identified and, interestingly, the study showed that the OX40 ligand (OX40-L)OX40 axis is different from other pathways [79] . OX40-L, which belongs to the TNFR-TNF superfamily, is highly expressed by myeloid antigen-presenting cells ( 
OX40-L expression by myeloid APCs is induced by
RNPanti-RNP immune complexes through Toll-like receptor 7 activation [79] .
IL-21
Production of high levels of IL-21 is a hallmark of Tfh cells [29] . This cytokine, discovered in 2000, is a member of the type I cytokine family [80, 81] . IL-21 activity is mediated by a heterodimeric receptor, composed of the IL-21 receptor (IL-21R) and the common cytokine receptor g chain (gc) [82] , shared with other cytokines from the same family (IL-2, IL-4, IL-7, IL-9, IL-15). This receptor is expressed by many types of lymphoid and myeloid cells [81] . IL-21 is produced mainly by Tfh, Th17 cells and natural killer T cells [8386] . It is an immunomodulatory cytokine that has pleiotropic effects on both innate and adaptive immune cells [83] . IL-21 plays an important role in regulating CD4 + T cell differentiation [87, 88] 
Role of IL-21 in SLE pathogenesis
Importance of IL-21 in the pathogenesis of murine lupus
Using an induced lupus-like model of chronic graft vs host disease (GVHD), a previous study investigated the importance of IL-21 signalling in this model of autoimmunity. IL-21 was essential for promotion of the disease, with decreased B cell activation, plasma cell differentiation, autoantibody production or kidney disease severity in IL-21R À / À chronic GVHD mice [102] . Sanroque mice are also characterized by excessive production of IL-21 [55] . Additionally, in the BXSB-Yaa mouse model, animals present an increase in IL-21 mRNA levels in splenocytes as well as elevated serum levels of IL-21 compared with wildtype animals [95] . The increase in expression of IL-21 arises in a time-dependent manner in association with the development of disease [60] . In IL-21R-deficient BXSB-Yaa mice, serum levels of IgG1, IgG2b and IgG3, as well as serum levels of ANA, were greatly decreased [60] . IL-21R deficiency also prevented the characteristic renal disease and premature mortality [60] . These data suggest that IL-21 signalling is fundamental to the pathogenesis of SLE in BXSB-Yaa mice, and the authors have investigated the effects of therapeutic blockade of the IL-21 pathway by administrating IL-21R-Fc fusion protein. This treatment had partial anti-inflammatory activity, but induced only modest attenuation of the symptoms [103] . Nonetheless, it was noticed that the treatment decreased IgG1 serum levels, proteinuria levels and histological GN [103] . Interestingly, a biphasic response was observed with aggravation of disease associated with early treatment, whereas an advantageous effect is associated with later administration during disease [103] . Generating BXSB-Yaa mice selectively deficient in IL-21R on B cells, T cells or CD8 + T cells, the authors suggested that, in this murine model, IL-21 acts as a double-edged sword, with both pro-and anti-inflammatory roles: IL-21 signalling to B cells seems essential for the development of disease manifestation, but IL-21 signalling also induces expansion of central memory CD8 + suppressor cells that can inhibit disease progression [104] . IL-21R-Fc fusion protein was also tested in other murine models of SLE. In the MRL-Fas lpr mouse model, IL-21 dramatically increases in vitro B lymphocyte proliferation and antibody production [105] and IL-21R signalling is required for the characteristic accumulation of activated T and B cells, for spontaneous GC formation and for plasma cell accumulation [106] . IL-21R-Fc fusion protein reduced phenotypic disease severity, with a reduction in renal disease, lymphadenopathy, skin lesions and production of autoantibodies [105] . Recently, blockade of IL-21R was tested in the NZB/NZW mouse model of SLE with a novel antibody [107] . Treatment is associated with a reduction in nephritis onset or attenuation of established nephritis, as well as a reduction in splenomegaly, concentrations of total IgG and dsDNA-specific IgG3, spontaneous lymphocyte activation and the frequency of Tfh cells [107] .
Genetic variants of IL-21 linked to human SLE
The pathogenesis of SLE involves genetic factors, and many studies have tried to identify genetic susceptibility factors [108] . A number of genetic studies prove the association of SLE with SNPs in the IL-21 or IL-21R gene. In 2008, Sawalha et al. [109] screened 1318 patients with SLE and 1318 controls. Three SNPs in the IL-21 gene were genotyped and two of them, rs907715 and rs2221903, were found to be significantly associated with SLE, in particular in the EuropeanAmerican population. No functional data were provided by the authors [109] . Later, four other studies analysed the association between these two polymorphisms and disease susceptibility, with heterogeneous and inconsistent results [110113] . Recently, a meta-analysis pooled the data and revealed that both polymorphisms are associated with SLE [114] .
Other polymorphisms in the IL-21 gene or in the IL2IL21 region have been explored and two of them were found to be associated with a significantly increased risk of SLE in non-European populations [113, 115] . One of these is associated with higher plasma levels of IL-21 [113] and the polymorphism in the IL2IL21 region (rs6822844) seems to influence a better response to rituximab [116] . Additionally, copy number variations of IL-21 are associated with disease [117] .
Finally, an association reported between a polymorphism within the IL-21R gene (rs3093301) and SLE within two independent and ethnically divergent (European and Hispanic) cohorts of patients compared with healthy subjects [116] . This allele is associated with a three times greater risk of malar rash in European female patients [118] .
IL-21 in human SLE
Plasma levels of IL-21 are significantly elevated in SLE patients compared with healthy controls [66, 113, 119, 120] and correlate with the number of Tfh cells [66] . High concentrations of IL-21 in blood are associated with disease severity and with disease markers, such as SLEDAI scores or serum C3 complement fraction [66] . Consistently, an increased frequency of IL-21-expressing CD4 + T cells was observed in SLE patients as compared with a control population [67, 68, 120122] , with a correlation with increased Th17 cells, decreased Treg cells and increased IgG + class-switched memory B cells [67] .
Stimulation of CD4 + T cells from SLE patients with 17b-oestradiol increased expression of IL-21 in a dose-and time-dependent manner, and this results secondarily in increased antibody production by B cells [120] . Interestingly, a slight increase in IL-21 mRNA expression was seen in skin biopsy samples of SLE patients compared with controls [123] .
Conclusions
Observations in animal models and in humans provide strong evidence that inhibition of Tfh cells can have a therapeutic benefit in the treatment of lupus patients, and they may represent an important target for developing new drugs. 
